University of Michigan researchers have discovered a biomarker that may be a potentially important breakthrough in diagnosing and treating prostate cancer.
A new study finds that many women diagnosed with breast cancer are concerned about the genetic risk of developing other cancers themselves or of a loved one developing cancer.
Patients with chronic myelomonocytic leukemia have limited treatment options, and those that exist are effective only in fewer than half of patients. Now, a new study identifies a panel of genetic markers that predicted which tumor samples would likely respond to treatment.
Researchers have developed a new drug candidate that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.
The average lifetime risk of ovarian cancer is approximately 1.37 percent in non-Hispanic white women in the United States, but there are women at substantially higher and lower risk, according to the researchers, led by Celeste Leigh Pearce, associate professor of epidemiology.
The University of Michigan Comprehensive Cancer Center received a $1.65 million gift from the Hirair and Anna Hovnanian Foundation to fund adrenal cancer research.
In a randomized phase 3 trial, adrenal cancer patients receiving the investigational drug linsitinib fared no better than patients receiving a placebo. But the researchers noticed a small subset of patients who had significant response and remained on the drug for an extended time.
Researchers used the proton pump inhibitor omeprazole, a commonly used acid inhibitor, in combination with naproxen and found it was effective at preventing bladder cancer in an animal model.
Theodore S. Lawrence, M.D., Ph.D., has been named the director of the University of Michigan Comprehensive Cancer Center. Lawrence, who is also chair of radiation oncology, succeeds founding director Max S. Wicha, M.D.
Uterine sarcoma was found in 0.22% of women following a hysterectomy for benign conditions, a new study finds. This may have implications for the risks associated with controversial power morcellation procedures.